Rosetta Genomics last week reported a drop in its first-quarter loss as it trimmed business costs and research and development spending.

For the three-month period ended March 30, the company's net loss fell to $1.7 million, or $0.07 per share, from a year-ago loss of $3.7 million, or $0.23 per share.

R&D expenses in the quarter shrank to $1 million from $1.6 million in the same period a year earlier, while marketing and business costs dropped to $625,000 from $1.2 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.